AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 162 min read$MDXG

MIMEDX GROUP, INC. (MDXG): Submission of Matters to a Vote of Security Holders

MIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-3.2 2 bylaws-amendedrestated2026.htm EX-3.2 Document Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MIMEDX GROUP, INC. ARTICLE I Corporate Offices Section 1. Principal and Registered Offices . The principal office of MiMedx Group, Inc. (the “ Corporation ”) shall be located at suc

Original reporting
SEC EDGAR 8-K
Published Jun 16, 2026, 8:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$MDXG
Neutral
low confidence
Mentioned
$MDXG
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MDXGNeutralLow
01

Why it matters

The excerpt describes governance provisions (principal office, meeting location/remote meetings, annual and special meeting mechanics, and shareholder-request procedures) but does not report any vote results or corporate action outcomes.

02

Market read

Primarily a governance/administrative update; no new financial guidance, contract, or enforcement action is disclosed in the provided text.

03

What to watch

Traders may want to check the full 8-K for any additional items beyond Item 5.07 (e.g., director elections, vote results, or other corporate actions) that are not shown in the scraped excerpt.

Relevance 6/10Novelty 3/10Timing: Filed June 16, 2026 (8-K)

Background

The filing is an SEC Form 8-K under Item 5.07, attaching amended and restated bylaws as Exhibit 3.2.

Company-level read

Ticker impact

$MDXGNeutralLow confidence
Context

MiMedx Group filed an 8-K exhibit amending and restating its bylaws, including shareholder meeting and special-meeting procedures.

Expected impact

Low likelihood of immediate price impact; any effect would be indirect via governance/activism expectations.

Evidence & confidence

The disclosure is procedural (bylaws text) with no vote outcomes, deal terms, or new business/financial guidance.

Market effects

Sector

Minimal; governance-document updates are company-specific and not a sector datapoint.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the bylaws amendment tightens or clarifies special-meeting thresholds, it could marginally change activist/board-contest dynamics—though the excerpt provides no explicit change details or outcomes.

Key entities

  • issuer
    MiMedx Group, Inc.

    Subject of the 8-K; amended and restated bylaws were filed as Exhibit 3.2 under Item 5.07.

Read at source← All news

Related articles

JUL 31
$MDXGMedAI 9/10

MiMedx to acquire Sanara MedTech in $350M deal

MiMedx Group agreed to acquire Sanara MedTech in a cash-and-stock deal valued at about $350 million enterprise value, per MiMedx’s July 30 release. Sanara shareholders will receive $33 cash plus 0.4735 MiMedx shares per share, totaling $35 per share. The stock value uses MiMedx’s $4.22 average price. Deal expected to close by year-end, subject to approvals; combined 2027 revenue projected above $400 million.

beckersspine.com4 min
JUL 30
$MDXGHighAI 10/10

MIMEDX to Acquire Sanara MedTech – Ortho Spine News

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm...

orthospinenews.com4 min
JUL 30
$MDXGHighAI 9/10

MiMedx To Acquire Sanara MedTech In $350 Million Deal; Stock Up

MiMed Group Inc. (MDXG) agreed to acquire Sanara MedTech Inc. (SMTI) for $35 per share, about $350 million. Sanara’s products include CellerateRX and BIASURGE, and it plans a 2027 launch of OsStic BioAdhesive, FDA Breakthrough-designated. MiMedx projects combined 2027 revenue over $400 million and adjusted EBITDA margins above 20%, with $20M+ synergies. SMTI is up 12.1% to $33.91.

rttnews.com4 min
JUL 30
$MDXGMed

MiMedx: Q2 Earnings Snapshot

MiMedx Group Inc. (MDXG) reported a Q2 loss of $14.8 million, or 10 cents per share. Adjusted for non-recurring items, it posted a 5 cents per share loss. Revenue was $64.4 million. The company expects full-year revenue of $260 million to $290 million.

local3news.com2 min
JUL 30
$SPRCHighAI 8/10

Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

rttnews.com3 min